Ticker: VRTX | Published: 2026-09-22
VRTX jumps on drug data
Vertex is rallying moderately after announcing positive Phase 2b AMPLIFIED results for inaxaplin, a direct company-specific catalyst, with a pre-market dip quickly reversing as traders digested the news.
Sources: https://www.businesswire.com/news/home/20260921995768/en/, https://es.marketscreener.com/noticias/vertex-pharmaceuticals-anuncia-resultados-positi